Innate Pharma updates pipeline timelines in Q3 2026 report

Innate Pharma reported its business and financial update for the third quarter of 2026 on November 5, 2026.

The company said IPH4502 is its proprietary ADC targeting Nectin-4, built with a differentiated antibody, a proprietary stable linker, and an exatecan payload, designed with the potential to overcome resistance to Enfortumab Vedotin in urothelial carcinoma and to address tumors with low or heterogeneous Nectin-4 expression beyond urothelial carcinoma, and it is being tested in a Phase 1 trial called IPH4502-101 (NCT06781983) in solid tumors known to express Nectin-4.¹ Enrollment in the Phase 1 dose-escalation portion of that study was completed as announced in July 2026, with 76 patients enrolled across multiple solid tumor types.¹ Dose-escalation data will be presented as a poster at the ENA Symposium in Barcelona on November 18, 2026, followed by a hybrid event in London with a live webcast.¹

For lacutamab, developed with Sobi, Innate is advancing the Phase 3 TELLOMAK-3 confirmatory study in cutaneous T cell lymphoma, with first patient dosing expected in the first quarter of 2027.¹ The trial includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.¹ The company said it plans to file for FDA accelerated approval in Sézary syndrome in the second half of 2027, using existing Phase 2 TELLOMAK data, once the Phase 3 study is underway.¹

On monalizumab, partnered with AstraZeneca, enrollment is complete in the AstraZeneca-sponsored Phase 3 PACIFIC-9 trial testing durvalumab combined with monalizumab or oleclumab in unresectable Stage III NSCLC patients who have not progressed after platinum-based chemoradiation.¹ AstraZeneca pushed back the expected timing of the trial's high-level data readout to the first half of 2027 from the previously stated second half of 2026, citing the event-driven design of the study.¹

The company reported a cash position of €96.8 million as of September 30, 2026, with an anticipated cash horizon to the end of the first quarter of 2028.¹ Chief Financial Officer Frédéric Lombard will step down on December 31, 2026.¹